NCT01894048View on ClinicalTrials.gov

Targeted Small Airways Therapy in Persistent Asthma

PHASE4CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 28, 2013

Primary Completion Date

June 25, 2018

Study Completion Date

June 25, 2018

Conditions
Asthma
Interventions
DRUG

Qvar® (beclometasone dipropionate HFA)

Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.

Trial Locations (1)

DD1 3AU

Brian Lipworth, Dundee

All Listed Sponsors
collaborator

Teva Pharmaceuticals USA

INDUSTRY

lead

University of Dundee

OTHER

NCT01894048 - Targeted Small Airways Therapy in Persistent Asthma | Biotech Hunter | Biotech Hunter